Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $99.5 million.

  • vTv Therapeutics' Liabilities and Shareholders Equity rose 13050.23% to $99.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.2 million, marking a year-over-year increase of 2674.8%. This contributed to the annual value of $38.3 million for FY2024, which is 24730.44% up from last year.
  • According to the latest figures from Q3 2025, vTv Therapeutics' Liabilities and Shareholders Equity is $99.5 million, which was up 13050.23% from $26.4 million recorded in Q2 2025.
  • Over the past 5 years, vTv Therapeutics' Liabilities and Shareholders Equity peaked at $99.5 million during Q3 2025, and registered a low of $11.0 million during Q4 2023.
  • For the 5-year period, vTv Therapeutics' Liabilities and Shareholders Equity averaged around $33.6 million, with its median value being $31.4 million (2021).
  • As far as peak fluctuations go, vTv Therapeutics' Liabilities and Shareholders Equity soared by 34612.55% in 2021, and later crashed by 6685.12% in 2023.
  • vTv Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $25.5 million in 2021, then soared by 30.48% to $33.2 million in 2022, then plummeted by 66.85% to $11.0 million in 2023, then surged by 247.3% to $38.3 million in 2024, then soared by 160.01% to $99.5 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $99.5 million for Q3 2025, versus $26.4 million for Q2 2025 and $32.0 million for Q1 2025.